Biotech Events And Company Events
MedImmune Works with NGM Biopharmaceuticals to Develop EEC-related Therapeutics
On June 17, 2013, AstraZeneca announced that its global biologics research and development branch—MedImmuneand and NGM Biopharmaceuticals, Inc. entered into an exclusive agreement to discover, develop and commercialize novel therapeutics from NGM’s enteroendocrine cell (EEC) programme.
GlaxoSmithKline’s Scientific Study Data was Questioned
There are always rumors and scandals. This time the “scandal” spread to scientific community and made GlaxoSmithKline (GSK) becoming the major topic of this week as a panel discusses the potential risks of the questioned drug. GSK, the London-based drug giant recently has conducted
The Market Trends of Elisa-kits
According to the GIA report, the US Research ELISA market is expected to reach $75 million by the year 2015. ELISA, or Enzyme-linked Immunosorbent Assay with the microtiter plate format, is a common technique for basic research and high throughput screening in laboratory and drug discovery
Creative BioMart Releases New products for H7N9 Research
During the past two months, China, especially the eastern China and the world suffered the threats of novel coronavirus— H7N9. Till May 27, 130 cases were diagnosed in mainland China. Until May 28, all the infected areas announced the stop of emergency response. But the stop
The 9th Annual International Conference on Predictive Human Toxicity and ADME/Tox Studies
The 9th Annual International Conference on Predictive Human Toxicity and ADME/Tox Studies 2014 will be held in Brussels, Belgium in January 2014. The exact time hasn’t published yet. The conference dedicated to advances in predicting human toxicities and screening earlier in the drug
The Building of Merck Serono was Bought by A Consortium
Left: Hansjörg Wyss; right: Ernesto Bertarelli. On May 22, 2013, it was reported that the former building of drug company Merck Serono in Geneva was bought by the two richest men in Switzerland: Hansjörg Wyss and Ernesto Bertarelli, actually to a consortium—Campus Biotech.
The 23rd Neuropharmacology Conference 2013
The Synaptic Basis of Neurodegenerative Disorders When Nov. 7, 2013 and Nov. 8, 2013 Where Sheraton San Diego Hotel and Marina, San Diego, United States Introduction The conference focuses on neuroscience field. There is increasing evidence that neurodegenerative diseases have at their
Worldwide Biotech/Biopharma Alliance (May 22, 2013～May 15, 2013)
On May 22, 2013, Agilent Technologies Inc., the Glyco-MEV laboratory at the University of Rouen, and Technology and Research (A*STAR) in Singapore signed a memorandum of understanding to work together to develop tools to effectively analyze biologics and vaccines. The biologics include molecules
The 2nd Anticancer Agents Congress: Targeting Cancer Stem Cell
When November 21 to 24th 2013 Where Belek, Antalya, Turkey (the congress hotel will be announced soon) Introduction Sponsored by EACR, the meeting aims to bring all kinds of anti-cancer agents researchers together and discuss recent achievements in the field of basic research on
Comparing Two Reproductive Cloning Methods: SCNT and iPS
I presumed that many of us still remember the infamous scientific research fraud in 2005, which originated in South Korea when some researchers claimed that they have created human embryonic stem cells via nuclear transfer. Since the geniture of Dolly with somatic cell nuclear transfer (SCNT) in
Block the Market Survival of Biosimilar?
Pharmaceutical is a quite important market for biology field. Among which, rare diseases attract relatively less attention, while complex diseases, such as cancer and immune diseases draw much. The as stake is also a promising market that could win tens of billions of dollars for expensive
The 2013 World Biotechnology Congress
When June 3-6, 2013 Where 900 Boylston Street, Hynes Convention Center, Boston, MA, United States Introduction The World Biotechnology Congress 2013 is dedicated to developments and advances in biotechnology research. It will gather Pharmaceutical Scientists, Biotechnologists, Clinicians,
The 2013 Asia Antibody Congress
When June 10-13, 2013 Where 392 Havelock Road, Grand Copthorne Waterfront Hotel, Singapore Introduction The 2013 Asia Antibody Congress is organized by Terrapinn. It will serve as a strategic platform for pharmas, biotechs, research institutes and solution providers to discuss key
Worldwide Biotech/Biopharma Alliance (May 9, 2013～May 6, 2013)
On May 9, 2013, GlaxoSmithKline and Merck are slashing the prices of their HPV vaccinations in a deal with the GAVI Alliance, which delivers immunizations to the developing world. It's the first big push to protect girls in poor countries from the human papillomavirus, which can cause cervical
The Exclusive Right Buyout of Sanofi’s Ophthalmology Antibodies by Regeneron
Sanofi and Regeneron are old partners that have worked together for many times and gained achievements, for example the colon-cancer drug Zaltrap and REGN727. On May 3, 2013, Regeneron Pharmaceuticals announced two preclinical programs for its growing business in ophthalmology drugs and it has
A New Round of Investment from Capital Royalty for Biotech and Healthcare Industries
On May 2, 2013, Capital Royalty announced that it had gathered an $805 million investment fund to back a new round of loans and royalty deals with biotechs, pharma and other healthcare companies if they are looking for other financing. For example, Capital Royalty had its largest investment for
Soligenix Collaborates with Intrexon on Promoting Monoclonal Antibody Therapy for Melioidosis
On May 1, 2013, Soligenix, Inc., a biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures announced its collaboration between Intrexon to develop a treatment for Melioidosis. Intrexon is a synthetic biology company that utilizes its
International Symposium: Molecular Life Sciences 2013
When Oct. 3, 2013 to Oct. 6, 2013 Where Campus Westend, Goethe University, Frankfurt am Main, Germany Introduction This symposium is organized by German Society for Biochemistry and Molecular Biology (GBM). This is a small scale conference. The meeting covers the major aspects of molecular
Eli Lilly Was Involved in Patent Suit by Johnson & Johnson
Eli Lilly, the 10th largest pharmaceutical company in the world, Johnson & Johnson (J&J), a multinational medical device, pharmaceutical and consumer packaged goods manufacturer were recently involved in court issues according to the report of Bloomberg. With a new late-stage study
The 4th Annual Therapeutic Protein Production Conference
When 15th May, 2013 Where Gunnels Wood Road, Stevenage, Hertfordshire, United Kingdom Introduction This is a small conference. Organized by Euroscicon, the conference aims to look at the challenges facing therapeutic protein production and demystify some of the novel approaches and new
Cerecor Acquired COMT Inhibitors and MK-0657 Rights from Merck
On Apr. 19, 2013, Cerecor, a Baltimore-based biotech focused on neuroscience, has picked up two CNS programs from the U.S. drug giant Merck. Cerecor acquired the exclusive global rights to MK-0657, an NR2B antagonist, as well as similar rights to catechol-O-methyltransferase (COMT) (which was
One of the Biggest Company Acquisition Cases in Life Science
According to Reuters report, Life Technologies Corp. has accepted the cash acquisition offered by Thermo Fisher Scientific for 13.6 billion on April 15, 2013. So far, the company takeover becomes one of the biggest acquisition cases in life science field. Life Technologies is a biotech tool
5th International Conference on Crossroads between Innate and Adaptive Immunity
When Sep. 21, 2013 to Sep. 26, 2013 Where Grecotel Imperial Conference Center, Corfu, Greece Introduction Theme-based on immunology, the conference is organized by Aegean. It is well recognized that dendritic cells, NK cells, NK-T cells and T cells are all critical for the host
Worldwide Biotech/Biopharma Alliance (Apr. 12, 2013～Apr. 8, 2013)
On Apr. 12, 2013, Carbios announced the signature of a pivotal €7-million collaboration with the French National Institute for Agricultural Research (INRA) at the Toulouse White Biotechnology (TWB) research center. The INRA groups will focus on enzyme screening, enzymatic catalysis and cell
The Translational Kinase Tumor Inhibitor Discovery Consortium between Six Partners
On April 10, 2013, SARomics Biostructures, Prestwick Chemical and ProQinase together with the University of Turin, Italy, the Israel Structural Proteomics Center (ISPC) and the TechMedIll platform of the University of Strasbourg announced that they have created the Translational Kinase Tumor
